Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,050 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.
Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, De Keulenaer G, Dei Cas A, González A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Riksen NP, Rosano G, Staels B, van Laake LW, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA, Heymans S. Maack C, et al. Among authors: wanner c. Eur Heart J. 2018 Dec 21;39(48):4243-4254. doi: 10.1093/eurheartj/ehy596. Eur Heart J. 2018. PMID: 30295797 Free PMC article. No abstract available.
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. Fruchart JC, et al. Among authors: wanner c. Am J Cardiol. 2008 Nov 17;102(10 Suppl):1K-34K. doi: 10.1016/S0002-9149(08)01833-X. Am J Cardiol. 2008. PMID: 19068318 Review.
High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.
Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM; NECOSAD Study Group. Drechsler C, et al. Among authors: wanner c. Nephrol Dial Transplant. 2015 Feb;30(2):288-93. doi: 10.1093/ndt/gfu301. Epub 2014 Sep 23. Nephrol Dial Transplant. 2015. PMID: 25248363
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies.
Drechsler C, Delgado G, Wanner C, Blouin K, Pilz S, Tomaschitz A, Kleber ME, Dressel A, Willmes C, Krane V, Krämer BK, März W, Ritz E, van Gilst WH, van der Harst P, de Boer RA. Drechsler C, et al. Among authors: wanner c. J Am Soc Nephrol. 2015 Sep;26(9):2213-21. doi: 10.1681/ASN.2014010093. Epub 2015 Jan 7. J Am Soc Nephrol. 2015. PMID: 25568176 Free PMC article.
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.
Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F. Rossignol P, et al. Among authors: wanner c. Eur Heart J. 2019 Mar 14;40(11):880-886. doi: 10.1093/eurheartj/ehx209. Eur Heart J. 2019. PMID: 28431138 Free PMC article.
Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV survey of the European Society of Cardiology.
Wagner M, Wanner C, Kotseva K, Wood D, De Bacquer D, Rydén L, Störk S, Heuschmann PU; EUROASPIRE IV investigators. Wagner M, et al. Among authors: wanner c. Eur J Prev Cardiol. 2017 Jul;24(11):1168-1180. doi: 10.1177/2047487317708891. Epub 2017 May 15. Eur J Prev Cardiol. 2017. PMID: 28503987 Free article.
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program. Butler J, et al. Among authors: wanner c. Eur J Heart Fail. 2017 Nov;19(11):1390-1400. doi: 10.1002/ejhf.933. Epub 2017 Aug 24. Eur J Heart Fail. 2017. PMID: 28836359 Free article. Review.
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Fitchett D, et al. Among authors: wanner c. Eur Heart J. 2018 Feb 1;39(5):363-370. doi: 10.1093/eurheartj/ehx511. Eur Heart J. 2018. PMID: 29020355 Clinical Trial.
1,050 results